138 related articles for article (PubMed ID: 26931498)
1. The Risk of Glioblastoma with TNF Inhibitors.
Guo M; Luo H; Samii A; Etminan M
Pharmacotherapy; 2016 Apr; 36(4):449-54. PubMed ID: 26931498
[TBL] [Abstract][Full Text] [Related]
2. Safety profiles of adalimumab, etanercept and infliximab: a pharmacovigilance study using a measure of disproportionality in a database of spontaneously reported adverse events.
Mendes D; Alves C; Batel-Marques F
J Clin Pharm Ther; 2014 Jun; 39(3):307-13. PubMed ID: 24635532
[TBL] [Abstract][Full Text] [Related]
3. Age-related trends in injection site reaction incidence induced by the tumor necrosis factor-α (TNF-α) inhibitors etanercept and adalimumab: the Food and Drug Administration adverse event reporting system, 2004-2015.
Matsui T; Umetsu R; Kato Y; Hane Y; Sasaoka S; Motooka Y; Hatahira H; Abe J; Fukuda A; Naganuma M; Kinosada Y; Nakamura M
Int J Med Sci; 2017; 14(2):102-109. PubMed ID: 28260984
[TBL] [Abstract][Full Text] [Related]
4. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
Welch HK; Kellum JA; Kane-Gill SL
Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
[TBL] [Abstract][Full Text] [Related]
5. Serious infection during etanercept, infliximab and adalimumab therapy for rheumatoid arthritis: A literature review.
Downey C
Int J Rheum Dis; 2016 Jun; 19(6):536-50. PubMed ID: 26200188
[TBL] [Abstract][Full Text] [Related]
6. Characterization of auto-immune hepatitis associated with the use of anti-TNFα agents: An analysis of 389 cases in VigiBase.
Vollmer O; Felten R; Mertz P; Lebrun-Vignes B; Salem JE; Arnaud L
Autoimmun Rev; 2020 Mar; 19(3):102460. PubMed ID: 31917266
[TBL] [Abstract][Full Text] [Related]
7. Statin-associated lower urinary tract symptoms: data mining of the public version of the FDA adverse event reporting system, FAERS.
Fujimoto M; Hosomi K; Takada M
Int J Clin Pharmacol Ther; 2014 Apr; 52(4):259-66. PubMed ID: 24472404
[TBL] [Abstract][Full Text] [Related]
8. Cardiotoxicity in targeted therapy for breast cancer: A study of the FDA adverse event reporting system (FAERS).
Wittayanukorn S; Qian J; Johnson BS; Hansen RA
J Oncol Pharm Pract; 2017 Mar; 23(2):93-102. PubMed ID: 26661047
[TBL] [Abstract][Full Text] [Related]
9. Assessment of acute kidney injury related to small-molecule protein kinase inhibitors using the FDA adverse event reporting system.
Fan Q; Ma J; Zhang B; Li Q; Liu F; Zhao B
Cancer Chemother Pharmacol; 2020 Nov; 86(5):655-662. PubMed ID: 33001273
[TBL] [Abstract][Full Text] [Related]
10. Comparison of signal detection of tumour necrosis factor-α inhibitors using the Korea Adverse Events Reporting System Database, 2005-2016.
Ha D; Lee SE; Song I; Lim SJ; Shin JY
Clin Rheumatol; 2020 Feb; 39(2):347-355. PubMed ID: 31673980
[TBL] [Abstract][Full Text] [Related]
11. Multiple sclerosis as an adverse drug reaction: clues from the FDA Adverse Event Reporting System.
Antonazzo IC; Raschi E; Forcesi E; Riise T; Bjornevik K; Baldin E; De Ponti F; Poluzzi E
Expert Opin Drug Saf; 2018 Sep; 17(9):869-874. PubMed ID: 30058390
[TBL] [Abstract][Full Text] [Related]
12. Potential cerebrovascular accident signal for risankizumab: A disproportionality analysis of the FDA Adverse Event Reporting System (FAERS).
Woods RH
Br J Clin Pharmacol; 2023 Aug; 89(8):2386-2395. PubMed ID: 36321844
[TBL] [Abstract][Full Text] [Related]
13. TNF inhibition for ophthalmic indications: current status and outlook.
Rifkin LM; Birnbaum AD; Goldstein DA
BioDrugs; 2013 Aug; 27(4):347-57. PubMed ID: 23568177
[TBL] [Abstract][Full Text] [Related]
14. Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors.
Verden A; Dimbil M; Kyle R; Overstreet B; Hoffman KB
Drug Saf; 2018 Apr; 41(4):357-361. PubMed ID: 29196988
[TBL] [Abstract][Full Text] [Related]
15. Comparison of post-marketing surveillance approaches regarding infections related to tumor necrosis factor inhibitors (TNFi's) used in treatment of autoimmune diseases.
Chen C; Borrego ME; Roberts MH; Raisch DW
Expert Opin Drug Saf; 2019 Aug; 18(8):733-744. PubMed ID: 31173698
[No Abstract] [Full Text] [Related]
16. Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.
Favalli EG; Pregnolato F; Biggioggero M; Becciolini A; Penatti AE; Marchesoni A; Meroni PL
Arthritis Care Res (Hoboken); 2016 Apr; 68(4):432-9. PubMed ID: 26556048
[TBL] [Abstract][Full Text] [Related]
17. Osteonecrosis of the Jaw in the United States Food and Drug Administration's Adverse Event Reporting System (FAERS).
Zhang X; Hamadeh IS; Song S; Katz J; Moreb JS; Langaee TY; Lesko LJ; Gong Y
J Bone Miner Res; 2016 Feb; 31(2):336-40. PubMed ID: 26288087
[TBL] [Abstract][Full Text] [Related]
18. Risk of malignant lymphoma in patients with rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs and methotrexate
.
Inose R; Hosomi K; Takahashi K; Yokoyama S; Takada M
Int J Clin Pharmacol Ther; 2019 Feb; 57(2):63-72. PubMed ID: 30526810
[TBL] [Abstract][Full Text] [Related]
19. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
20. Direct Comparative Effectiveness Among 3 Anti-Tumor Necrosis Factor Biologics in a Real-Life Cohort of Patients With Rheumatoid Arthritis.
Santos-Moreno P; Sánchez G; Gómez D; Bello-Gualtero J; Castro C
J Clin Rheumatol; 2016 Mar; 22(2):57-62. PubMed ID: 26886438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
